Alpharma: The Payment and the Pitch

Alpharma agreed to pay $42.5 million in the Alpharma Kadian settlement over alleged prescriber kickbacks and misrepresentations about the pain drug’s safety and effectiveness. A whistleblower brought the False Claims Act case over the marketing of Kadian.

The Justice Department announced the civil settlement on March 16, 2010. Alpharma, an American pharmaceutical manufacturer, was then a wholly owned subsidiary of King Pharmaceuticals.

What Were the Kadian Allegations?

The Kadian allegations covered payments intended to induce healthcare providers to promote or prescribe the drug, alongside misrepresentations about its safety and efficacy. The government placed both kinds of conduct between January 1, 2000 and December 29, 2008.

Kadian is a morphine-based drug used to treat chronic moderate to severe pain. A claim about how well a pain medicine works, or how safe it is, goes directly to the decision the prescriber makes for the patient.

The government alleged that Alpharma influenced the prescribing decision from both directions: the payment behind it and the information supporting it. Patients needed treatment decisions they could trust. Taxpayers’ money was at stake when public programs paid for those prescriptions.

How Do Pharmaceutical Kickbacks Work?

Pharmaceutical kickbacks work by offering money or another benefit to influence decisions that generate drug business. In the Kadian case, the government alleged that Alpharma paid health care providers to promote or prescribe its product. The commercial objective was the provider’s recommendation.

A manufacturer can influence the prescription even though a pharmacy or provider submits the reimbursement claim. The False Claims Act reaches a company that knowingly causes a false claim to be submitted. That is how a sales decision inside a drug company can become a case about public money outside it.

A payment approval shows the benefit, a sales instruction its purpose, and the government claim the public money involved. We connect those records with the insider who understands them, even when their view covers only one part of the business.

The Kadian resolution included both federal and state claims. The money at issue extended beyond the relationship between a manufacturer and a prescriber to the public programs funding care.

How Alpharma Reached the Prescriber

Alpharma’s sales representatives called on doctors and pharmacies to encourage prescribing or stocking its products over competitors’ products. A federal court opinion in a separate wage case describes that sales operation. The dispute was about representatives’ overtime pay, and its account gives a concrete view of the work behind a pharmaceutical sales pitch.

Alpharma told the court that each representative received a territory list of 500 physicians and chose approximately 120 to pursue. Representatives planned their routes and prepared annual business plans describing how they would grow the business. The company emphasized their freedom to decide whom to visit and how to approach them.

The representatives described tight control over the message. They said Alpharma directed them to use company scripts and supplied handouts and promotional literature they could not alter. For Kadian’s effectiveness, they said they were trained to follow the package insert.

Those accounts distinguish control of a territory from control of a product claim. A representative might choose the next doctor’s office while the company chooses the words carried into it. For an insider who knows a promotional statement was misleading, the script, training and approved material can show where that statement came from.

The annual business plan adds another view: whom the company hoped to reach and what the representative intended to accomplish. Paired with the actual message, it can help explain the purpose and audience of a sales campaign. That is why knowledge of how a territory operated can matter alongside knowledge of a particular payment.

When a Fee Pays for Prescribing

The purpose of a physician payment can be concealed by the name given to it. A separate Merck settlement announced in 2008 resolved allegations that excess payments to physicians were disguised as fees for training, consultation or market research. The government alleged that sales representatives used the programs to induce physicians to use Merck products.

That parallel makes the payment question concrete. What work did the manufacturer say it was buying, what work happened, and what business did it expect in return? An invoice gives the transaction a label. The instructions and actual work explain its purpose.

In speaker-program cases, the invitation and fee can be tied to prescribing. With advisory-board payments, the work behind an honorarium matters. An employee who knows why a physician was selected may understand a payment better than someone looking only at its accounting category.

Kadian Safety and Efficacy Claims

The government’s Kadian allegations also concerned what Alpharma said about the drug’s safety and effectiveness. That part of the case makes the promotional message itself important: the words used, the material behind them and who decided they should reach prescribers.

The Nordic Cochrane Centre’s 2012 paper Corporate Crime in the Pharmaceutical Industry Is Common, Serious and Repetitive reviewed cases involving large drug companies and identified recurring practices including misrepresented research results, hidden data on harms and kickbacks. Its account shows why financial influence and the quality of the medical message deserve attention together.

For cases involving distorted clinical evidence, the comparison is between the evidence and what the company represented. In a promotional case, that comparison also reaches the message delivered in the doctor’s office. Our work with an insider connects what the company knew, what it told prescribers and the government-paid business affected.

The Federal and State Settlement Shares

The Alpharma agreement allocated roughly $33.6 million to resolve federal claims and approximately $8.9 million to resolve state claims.

The announcement also allocated $5.33 million from the federal recovery to the whistleblower who brought the case.

How Much Money Do Pharmaceutical Whistleblowers Get?

A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.

The value a pharmaceutical whistleblower brings can be knowledge that connects records kept for different purposes. Sales staff may know the message and the target physician. Finance staff may know the approved payment. Medical or compliance staff may know the information behind a product claim. We build the case around how those pieces fit the conduct and the public money involved.

You Know the Payment or the Pitch

If you saw a prescriber payment tied to sales or a safety claim pushed beyond its evidence, speak with our whistleblower experts about the payment or the pitch. We work with you to turn that knowledge into your strongest pharmaceutical whistleblower case and bring in pharmaceutical fraud whistleblower lawyers who understand prescriber inducements and misleading promotion. We stay beside you as the case moves from the company’s internal decisions to the government’s recovery.